Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Sells 36,599 Shares of Stock

Key Points

• Insider Najat Khan sold 36,599 shares of Recursion Pharmaceuticals at an average price of $5.52, totaling approximately $202,026, which decreased their ownership by 5.19%.
• Recursion Pharmaceuticals reported a loss of $0.41 EPS in its latest quarter, missing estimates, despite a revenue increase of 33.3% year-over-year, totaling $19.10 million.
• The company has a current market cap of $2.21 billion with a consensus rating of "Hold" from analysts and a target price of $7.00.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) insider Najat Khan sold 36,599 shares of Recursion Pharmaceuticals stock in a transaction on Monday, August 18th. The stock was sold at an average price of $5.52, for a total transaction of $202,026.48. Following the completion of the transaction, the insider directly owned 668,197 shares in the company, valued at approximately $3,688,447.44. The trade was a 5.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Recursion Pharmaceuticals Trading Down 7.8%

Shares of NASDAQ RXRX traded down $0.43 during mid-day trading on Tuesday, hitting $5.09. The stock had a trading volume of 20,005,249 shares, compared to its average volume of 22,043,298. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.58 and a current ratio of 3.58. Recursion Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $12.36. The business has a 50 day moving average price of $5.48 and a two-hundred day moving average price of $5.80. The firm has a market cap of $2.21 billion, a P/E ratio of -2.86 and a beta of 0.93.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The firm had revenue of $19.10 million during the quarter, compared to analysts' expectations of $15.38 million. During the same period in the previous year, the firm earned ($0.40) earnings per share. The firm's quarterly revenue was up 33.3% compared to the same quarter last year. On average, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

RXRX has been the topic of a number of research analyst reports. Needham & Company LLC reissued a "buy" rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Tuesday, July 8th. Morgan Stanley initiated coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 price objective on the stock. Two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $7.00.

Institutional Trading of Recursion Pharmaceuticals

A number of hedge funds have recently modified their holdings of RXRX. Softbank Group CORP. bought a new position in Recursion Pharmaceuticals in the 4th quarter worth about $99,152,000. Novo Holdings A S bought a new position in Recursion Pharmaceuticals in the 4th quarter worth about $68,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Recursion Pharmaceuticals by 183.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company's stock worth $33,901,000 after purchasing an additional 4,149,346 shares in the last quarter. Norges Bank bought a new position in Recursion Pharmaceuticals in the 2nd quarter worth about $16,040,000. Finally, ARK Investment Management LLC boosted its stake in Recursion Pharmaceuticals by 7.6% in the 1st quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company's stock worth $184,174,000 after purchasing an additional 2,469,104 shares in the last quarter. Institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.